ADPS™
JAK2 V617F Mutation Test Kit
Ultra-Sensitivity Enhancing JAK2 V617F Research Outcomes
Ultra-Sensitivity Enhancing JAK2 V617F Research Outcomes
The JAK2 gene is located on chromosome 9p24 and is involved in the signal transduction pathways of hematopoiesis and the immune system. Mutations in the JAK2 gene are used as disease markers for myeloproliferative neoplasms (MPNs).
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers that originate from bone marrow stem cells and are associated with an increased risk of thrombosis and secondary leukemia. There are three main types of MPN: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PMF can occur alone, or it can start with ET or PV and develop over time. The diagnosis of MPN is usually made by bone marrow biopsy and genetic blood testing. The JAK2 V617F mutation (c.1849G>T) is found in MPNs such as PV (< 95%), ET (< 60%), and PMF (< 50%).
The ADPS™ JAK2 V617F Mutation Test Kit detects the JAK2 V617F mutation, which is highly associated with myeloproliferative tumors, with a detection sensitivity of 0.01%. It is designed for testing both tissue and plasma samples with a single kit.
This product is for research use only (RUO) and not intended for use in diagnostic procedures.
| Catalog No. | (RUO) R8005APA |
|---|---|
| Detection target | JAK2 V617F |
| Assay type | qPCR |
| Sample type | DNA extracted from blood and bone marrow |
| Master Mixture (MMX) |
1MMXs |
| Internal Control | JAK2 exon 4 |
| Detection Sensitivity | 0.01% |
| Detection Specificity | ≥ 99.0% |
| Precision (% CV) | ≤ 5% (CV, coefficient of variation) |
| Storage | -20±5℃ |
| Stability | 18 months |
| Freeze/Thaw stability | 5 times |
| Compatible Instruments | AB 7500 Fast, CFX96, QuantStudio5 |
ADPS™ Oncogene Mutation Test